CN4 COST-EFFECTIVENESS OF PEGYLATED LIPISOMAL DOXORUBICIN VS. CONVENTIONAL DOXORUBICIN IN AVOIDANCE OF CARDIOTOXICITY FOR METASTATIC BREAST CANCER IN THE FIRST TREATMENTYEAR
Nov 1, 2007, 00:00
10.1016/S1098-3015(10)64873-5
https://www.valueinhealthjournal.com/article/S1098-3015(10)64873-5/fulltext
Title :
CN4 COST-EFFECTIVENESS OF PEGYLATED LIPISOMAL DOXORUBICIN VS. CONVENTIONAL DOXORUBICIN IN AVOIDANCE OF CARDIOTOXICITY FOR METASTATIC BREAST CANCER IN THE FIRST TREATMENTYEAR
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)64873-5&doi=10.1016/S1098-3015(10)64873-5
First page :
Section Title :
Open access? :
No
Section Order :
32